Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares
March 04, 2024 at 01:02 am EST
Share
(Acquisition of own shares under the Articles of Incorporation pursuant to the provision of
Paragraph 2, Article 165 of the Companies Act)
Osaka, Japan, March 4, 2024 - Ono Pharmaceutical Co., Ltd. (President and CEO, Gyo Sagara; "the Company") today announced that it has acquired its own shares pursuant to the provision of Article 156 of the Companies Act, applied by replacing terms pursuant to the provision of Paragraph 3, Article 165 of the same Act, and that it has completed the acquisition of its own shares in accordance with the resolution passed on July 25, 2023, pursuant to the provisions of Article 370 of the Companies Act (resolution by documents instead of resolution by board meetings).
Particulars
1.
Class of shares acquired:
Common stock of the Company
2.
Total number of shares acquired:
68,000 shares
3.
Total amount of acquisition cost:
169,625,650 yen
4.
Period of acquisition:
March 1, 2024 (execution base)
5.
Method for acquisition:
Purchased on the Tokyo Stock Exchange
(Reference)
Details of the resolution by documents instead of resolution at the meeting of Board of Directors on July 25, 2023
(1)
Class of shares to be acquired:
Common stock of the Company
(2)
Total number of shares to be acquired:
19 million shares (maximum)
(3.89% of the total outstanding shares excluding own shares)
(3)
Total amount of acquisition cost:
50.0 billion yen (maximum)
(4)
Period of acquisition:
August 1, 2023 to March 22, 2024
Accumulated Company's own shares acquired, pursuant to the resolution by documents instead of resolution at the meeting of Board of Directors as of March 1, 2024
(1)
Total number of shares acquired:
18,732,400 shares
(2)
Total amount of acquisition cost:
49,999,752,000 yen
Attachments
Original Link
Permalink
Disclaimer
ONO Pharmaceutical Co. Ltd. published this content on
04 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
04 March 2024 06:02:06 UTC.
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.